We make it straightforward for patients and their physicians to discover and support with accessing clinical trials. We empower patients and their families to know and understand their options, and make the best possible decisions regarding their treatment journey.
To help make this a reality, we built powerful technology that efficiently connects patients, physicians, trial sites and BioPharma, supporting straightforward and transparent access to drugs in development worldwide.
We’ve helped
A community of
Trusted by
Duchenne Muscular Dystrophy is the most common and severe type of muscular dystrophy. DMD is a genetic progressive muscle disorder caused by mutations on the dystrophin gene.
Duchenne Muscular Dystrophy is the most common and severe type of muscular dystrophy. DMD is a genetic progressive muscle disorder caused by mutations on the dystrophin gene.
There is currently no cure for Duchenne Muscular Dystrophy. Until recently, steroids were the only treatment available, but there are now several FDA-approved exon-skipping treatments. Many pharmaceutical companies are working to develop gene therapies.
Our team believes that every patient counts and every treatment option matters.
Join our team at myTomorrows and become part of a global mission. We conduct comprehensive searches worldwide, connecting patients and physicians to treatment options regardless of their location. Your work will contribute to a global network that has already assisted over 10,000 patients and 1,000 physicians in more than 80 countries.
Join our team at myTomorrows and become part of a global mission. We conduct comprehensive searches worldwide, connecting patients and physicians to treatment options regardless of their location. Your work will contribute to a global network that has already assisted over 10,000 patients and 1,000 physicians in more than 80 countries.
Join our team at myTomorrows and become part of a global mission. We conduct comprehensive searches worldwide, connecting patients and physicians to treatment options regardless of their location. Your work will contribute to a global network that has already assisted over 10,000 patients and 1,000 physicians in more than 80 countries.
“I started myTomorrows in 2012 after losing my father to an aggressive form of lung cancer. As a physician and founder of several biotech companies, I hoped my knowledge and connections would help him find and access a treatment in development. Instead, I was met with a shockingly slow and complicated process – I could only imagine how much more difficult it would be for someone with less time and resources.
I decided this had to change. I dedicated myself to creating an easier and faster way for patients to access treatments in development.
We have grown a lot since then, and our team of experts has helped patients in almost 50 countries. Our guiding principle remains the same: we believe every patient should have access to all possible treatment options.”
Ronald Brus, MD
myTomorrows founder
Our team believes that every patient counts and every treatment option matters.
Team 4 Position
Team 3 Position
Team 2 Position
Team 1 Position
Whether you are a patient, a healthcare professional, or a BioPharma specialist, we have something in store for you.
